Navigation Links
Genelux Corporation Appoints Catherine J. Mackey, PhD to Board of Directors
Date:8/4/2011

SAN DIEGO, Aug. 4, 2011 /PRNewswire/ -- Genelux Corporation, a privately held, clinical stage biopharmaceutical company developing diagnostic and therapeutic solutions for cancer and inflammatory diseases, today announced the appointment of Dr. Catherine J. Mackey, long-time Pfizer executive, to the Company's Board of Directors.

"In a career defined by excellence at every level, Dr. Mackey brings a unique set of skills and attributes that we believe will significantly complement and further strengthen the Genelux Board," said Aladar A. Szalay, Chairman and Chief Executive Officer. "Her 28 years of industry experience will be a valuable asset, particularly as we advance the Genelux product pipeline into later stage trials and prepare the company for the next stage of growth. Dr. Mackey's executive experience within a world class pharmaceutical R&D organization will help us to preserve the core of scientific innovation that has characterized Genelux Corporation. I am honored to welcome Catherine Mackey as our third outside Director".

Dr. Mackey is the founder and CEO of MindPiece Partners, a management consulting firm, and the former Sr. Vice President of Worldwide Research and Development for Pfizer Inc. She has 28 years of experience in the life science industry.

After receiving her B.S. and Ph.D. degrees in microbiology from Cornell University, Dr. Mackey spent the first part of her career in agricultural biotechnology. She worked her way up from bench scientist to Vice President and head of Research and Development for DEKALB Genetics Corporation. She was member of DEKALB's executive team which sold the company to Monsanto in 1998. Dr. Mackey joined Pfizer in 1999 to lead Genomic and Proteomic Sciences for human health in Groton, CT. Soon she was appointed Vice President and head of Strategic Alliances and in 2001 she was appointed Sr. Vice President of Pfizer Global R&D and Director of Pfizer La Jolla – a position she held for nine years. Dr. Mackey built Pfizer La Jolla into a vibrant R&D center of nearly 1000 people focused on the discovery and development of innovative medicines.

Dr. Mackey serves on several boards consistent with her passion for healthcare and innovation.

About Genelux Corporation

Genelux Corporation was founded in 2001 with a mission to develop safe and effective diagnostic and therapeutic solutions for cancer and inflammatory diseases for which there are no effective treatments today. Genelux Corporation is headquartered in San Diego, California.

Genelux Forward Looking Statement

Statements made about Genelux Corporation, other than statements of historical fact, reflect Management's current beliefs and assumptions founded on the data and information currently available to us. Statements of the company's progress, results, timing of pre-clinical and clinical trials and projections for product pipelines are examples of forward-looking statements. By definition, such undertakings involve risks, uncertainties and assumptions, and are subject to a number of such factors that could cause actual results to differ substantially from statements made, including but not limited to: risks associated with the success of clinical trials, research and development programs, regulatory approval processes for clinical trials, competitive technologies and products, patents, inception and/or continuation of corporate and other strategic partnerships and the need for additional funding or financing.


'/>"/>
SOURCE Genelux Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Genelux Corporation Expands Board of Directors, Appointing Dennis Fenton, Former Amgen Executive
2. Novocure Announces Long-Term Supply Agreement With ITT Corporation for Ceramic Sensor Technology
3. CytoSorbents Corporation to Exhibit at the Advanced Technology Applications for Combat Casualty Care Conference
4. I-Flow Corporation Enters into Exclusive Government Distribution Agreement With Buffalo Supply, Inc.
5. Techne Corporation Releases Unaudited Fourth Quarter and Fiscal Year 2011 Results
6. Upsher-Smith Laboratories Named Manufacturer of the Year by AmerisourceBergen Corporation
7. Spectros Corporation Year-To-Date Oximeter Sales Revenue Up 51% in First Half of 2011
8. Kensey Nash Corporation Announces Its Fourth Quarter and Fiscal Year End 2011 Earnings Release Date and Teleconference
9. DURECT Corporation Invites You to Join its Second Quarter 2011 Earnings Conference Call
10. Vystar® Corporation Spotlights Advantages of Vytex® NRL at the 13th Annual International Latex Conference
11. CVS Caremark Corporation to Hold Second Quarter 2011 Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... , Feb. 4, 2016 Worldwide Radiology ... significant growth as next generation systems provide a ... radiology for cancer surgery. New systems pinpoint the ... that has been such a problem previously, limiting ... Radiosurgery robots take cancer surgery far beyond what ...
(Date:2/4/2016)... LONDON , Feb. 4, 2016 ... Summary Global Markets Direct,s, ,Wegener Polyangiitis - ... the Wegener Polyangiitis,s therapeutic pipeline. This report ... Wegener Polyangiitis, complete with comparative analysis at various ... action (MoA), route of administration (RoA) and molecule ...
(Date:2/4/2016)... , Feb. 4, 2016 Global ... competitive market to drive long-term market growth ... common set of chronic disorders that affect 5–7% ... in terms of their symptoms and key patient ... dysregulation of immune pathways and an inappropriate immune ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... 08, 2016 , ... Joshua Rosenthal, PhD, Chief Scientific Officer ... use newly released government data on populations and physicians to better calculate risk ... the value they create to succeed in new economic models for value based ...
(Date:2/8/2016)... ... February 08, 2016 , ... The schedule is now online for ... 2016 Conference, which is being held May 25-29 at the Loews Chicago O’Hare Hotel, ... interventions and causes of chronic illness in children. , Very recent articles have cited ...
(Date:2/7/2016)... Lake Orion, Clarkston, Metamora, Michigan (PRWEB) , ... ... ... ability to correct pelvic organ prolapse with the latest techniques and the most ... greatest risk for pelvic organ prolapse, particularly after menopause. Other risk factors include ...
(Date:2/7/2016)... ... February 07, 2016 , ... HealthSmart Holdings, Inc. ... organizations with the tools and information to lower the costs, and increase the ... cost of providing employee healthcare benefits by as much as 22%:, + ...
(Date:2/6/2016)... ... February 06, 2016 , ... ... NURSES EXPECTED AT AORN SURGICAL CONFERENCE & EXPO , WHAT:     , This ... an estimated 5000 perioperative nurses in attendance to study the latest evidence-based ...
Breaking Medicine News(10 mins):